ArticleAIDS research and therapy2026
Cumulative effect of cotrimoxazole, isoniazid and opportunistic infection prophylaxis on CD4 response among people living with HIV on first-line ART in Ari Zone, Southern Ethiopia.
Article in AIDS research and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProphylactic medications are commonly used to prevent tuberculosis and opportunistic infections in people living with HIV (PLWH) who are on first-line antiretroviral therapy (ART). However, their cumulative influence on cluster of differentiation 4 (CD4) responses is still a subject of ongoing investigation.
methodsA retrospective chart review was conducted utilizing secondary data derived from medical records of 500 people living with HIV (≥ 15 years) who initiated first-line ART at Jinka General Hospital in Ari Zone, South Ethiopia, between September 2019 and January 2025. CD4 response was defined as an increase of ≥ 50 cells/µL from baseline to the most recent measurement. The most recent CD4 measurement taken up to January 2025 was used for analysis. The primary outcome measure was a binary variable for CD4 response, defined as an increase of ≥ 50 cells/µL from baseline to end-line counts. Multivariable binary logistic regression was used to assess independent and interaction effects of prophylactic therapies on CD4 response.
resultsAmong 500 participants, 50.2% demonstrated an improvement in CD4 count. Use of cotrimoxazole preventive therapy (CPT), isoniazid preventive therapy (IPT), and opportunistic infection (OI) medications was each independently associated with higher odds of CD4 improvement. However, interaction analysis showed that the CPT-OI combination and the triple CPT-IPT-OI regimen showed a statistically significant interaction suggesting a possible synergistic association with CD4 recovery beyond their individual additive effects. Predicted probabilities of CD4 improvement increased progressively with dual and triple prophylactic combinations compared with no prophylaxis.
conclusionThe combined use of prophylactic medications was significantly associated with CD4 recovery in people living with HIV on first-line ART. These findings emphasize the importance of integrated preventative strategies, particularly in resource-limited settings, and highlight the need for adherence support among individuals with limited formal education and those living in rural areas. The study's generalizability is limited, however, due to its single-center retrospective design and the use of a broad category for "OI prophylaxis" without specifying individual drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.